CP 47,497

CP 47,497

Chemical structure of CP 47,497

CP 47,497 is a synthetic cannabinoid that was developed in the 1980s by Pfizer as part of research into the endocannabinoid system. It is a potent agonist of the cannabinoid receptors, particularly the CB1 receptor.

Chemical Properties

CP 47,497 is a member of the cyclohexylphenol class of cannabinoids. Its chemical structure is characterized by a cyclohexyl group attached to a phenol moiety, which is similar to the structure of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Pharmacology

CP 47,497 acts as a full agonist at the CB1 receptor, which is primarily found in the central nervous system. This interaction is responsible for its psychoactive effects, which mimic those of THC. The compound also has affinity for the CB2 receptor, which is more prevalent in the immune system.

Effects

The effects of CP 47,497 are similar to those of THC, including euphoria, relaxation, and altered perception. However, due to its synthetic nature, the potency and duration of effects can vary significantly compared to natural cannabinoids.

Legal Status

Due to its psychoactive properties and potential for abuse, CP 47,497 has been classified as a controlled substance in many countries. It is often included in legislation targeting synthetic cannabinoids, which are sometimes sold as "spice" or "K2."

Research

Research into CP 47,497 and similar compounds has provided valuable insights into the functioning of the endocannabinoid system. These studies have implications for the development of new therapeutic agents targeting cannabinoid receptors.

Related pages

• Cannabinoid receptor
• Synthetic cannabinoids
• Endocannabinoid system
• Tetrahydrocannabinol